The experimental Novartis drug Ribociclib, when combined with an older drug, has shown the ability to fight the advancement of advanced breast cancer than the standard treatment on its own. This puts Ribociclib in a position to challenge the market dominance of Pfizer’s Ibrance, a drug embraced by oncologists upon its release and expected to hit 2.1 billion in sales this year.
Individuals who took Ribociclib in combination with Letrozole were 44% more likely to see no progression of their cancer nor succumb to it. This 44% reduction with no disease progress surpasses the 42% reported in late-stage trials of Ibrance. Ribociclib inhibits enzymes identified as Cyclin-dependent Kiases 4 & 6. Both Ibrace and Riociclib are targeted toward individuals with tumor growth attributable to estrogen and whose cancer is not attributable to HER2 Protein.
Ribiciclib and Ibrance are said to have similar side effects and levels of success. Similar to Ibrance, Ribociclib, it triggered a decline in white blood cells. It was also linked to signs of possible liver and heart issues.
Ribociclib performs in a manner similar to Ibrance and finds itself second in the advanced breast cancer treatment market with expectations being that it will be available in 2017, a full year ahead of Eli Lilly’s Abemaciclib.
Last August, Novartis won a breakthrough therapy designation from regulators for Ribociclib as an advanced breast cancer first-line treatment. What Ribociclib will cost is not yet known, but Pfizer’s Ibrance comes in at $10.000.00 a month.
In May 2016 Novartis revealed that its 600+ patient trial had been successful and fully revealed the findings at the European Society For Medical Oncology Congress in Copenhagen, Denmark, and additionally publishing the results in the NEJM online.